BioSpace News Archive

Zhongchao Inc. (NASDAQ: ZCMD) (“Zhongchao” or the “Company”), a healthcare services company offering patient management, online healthcare information, professional training and educational services, today announced that it co-organized a virtual panel session with the Chinese Association of Health Education and Promotion for the China -Ru

Company Focus on Shareholder Value Creation, Cash Preservation, Expense Reduction, Workforce Efficiency and Operational Synergies

EB-101 treatment of large, chronic wounds is associated with durable healing and pain relief in patients with RDEB Literature review of 65 studies confirms and expands understanding of substantial disease burden of RDEB with considerable clinical, economic and humanistic impact on patients and their families NEW YORK and CLEVELAND, July 10, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two post

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or “the Company”) today provided an update on progress with its SARS-CoV-2 (COVID-19) vaccine candidate and announced the termination of its clinical development program with AG013 for the treatment of severe oral mucositis in cancer patients. While working with Aragen Bioscience, a leading contract research

Ocumension Therapeutics (“Ocumension”), a China -based ophthalmic pharmaceutical platform company, has today launched its Initial Public Offering (IPO) of the company’s stock on The Stock Exchange of Hong Kong (HKEX). Ocumension plans to offer 105,930,000 shares priced at HK$14.66 each and will trade under the stock code “1477.HK”. Mor

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the second quarter of 2020 after market close on Thursday, August 13, 2020. A conference call hosted by Michael Guerriere, President and Chief Executive Officer and David Bacon, Senior Vice President and Chief Financial Officer, will be held on August 14, 2020, at 11:30 a.m. (ET) to discuss the results. To participa

Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced the conversion of accrued compensation due to the Company’s Chief Executive Officer, Chief Innovation Officer and two senior advisors to equity units with the same terms as the Company’s

Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced the pricing of its initial public offering of 14,000,000 shares of common stock at a public offering price of $18.00 per share.

The V Foundation Wine Celebration is going virtual on August 8, 2020 by presenting “MOMENTUM 2.0,” an immersive, digital auction experience supporting the V Foundation’s fight to achieve Victory Over Cancer®. Each year, as part of the annual event, the V Foundation Wine Celebration hosts the Answer for Cancer research symposium, where world-class

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Fluphenazine Hydrochloride Tablets USP, 1 mg, 2.5 mg, 5 mg, and 10 mg. Fluphenazine Hydrochloride is the generic version of Prolixin for treatment of schizophrenia. Amneal immediately initiate